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Studies on genome-wide transcription patterns have shown that many genetic alterations implicated in pheochromocytoma-
paraganglioma (P-PGL) syndromes cluster in a common cellular pathway leading to aberrant activation of molecular response
to hypoxia in normoxic conditions (the pseudohypoxia hypothesis). Several cases of P-PGL have been reported in patients with
cyanotic congenital heart disease (CCHD). Patients affected with CCHD have an increased likelihood of P-PGL compared to
those affected with noncyanotic congenital heart disease. One widely supported hypothesis is that chronic hypoxia represents the
determining factor supporting this increased risk. We report the case of a 23-year-old woman affected with congenital tricuspid
atresia surgically by the Fontan procedure. The patient was admitted to hospital with hypertensive crisis and dyspnea. Chest
computed tomography revealed, incidentally, a 6-cm mass in the left adrenal lodge. Increased levels of noradrenaline (NA) and
its metabolites were detected (plasma NA 5003.7 pg/ml, n.v.<480; urinary NA 1059.5𝜇g/24 h, n.v.<85.5; urinary metanephrine
489 𝜇g/24 h, n.v.<320).The patient did not report any additional symptom related to catecholamine excess. The left adrenal tumor
showed abnormal accumulation when 131I-metaiodobenzylguanidine scintigraphy was performed. A 18F-fluorodeoxyglucose
positron emission tomography showed no significant metabolic activity in the left adrenal gland but intense uptake in the supra-
and subdiaphragmatic brown adipose tissue, probably due to noradrenergic-stimulated glucose uptake. The patient underwent
left open adrenalectomy after preconditioning with 𝛼- and 𝛽-blockers and histopathological examination confirmed the diagnosis
of pheochromocytoma (Ki-67<5%). Screening for germline mutations did not show any genes mutation (investigated mutations:
RET, TMEM127,MAX, SDHD, SDHC, SDHB, SDHAF2, SDHA, andVHL). Clinicians should consider P-PGLwhen an unexplained
clinical deterioration occurs in CCHD patients, even in the absence of typical paroxysmal symptoms.
1. Introduction
Congenital heart disease (CHD) is a group of developmental
abnormalities of the heart and great vessels whose incidence
has considerably increased in the last decades. Cyanotic
congenital heart disease (CCHD) represents a severe subset
of CHD often characterized by neonatal systemic hypoxia.
In CCHD a right to left shunt is observed and it results
in deoxygenated blood entering the oxygenated limb of the
vascular circuit. CCHD affects 1/1000 live newborns and
represents approximately 10% of all CHD [1]. Early surgical
treatment allows in most cases the reduction or elimination
of chronic hypoxia.
Numerous case of congenital heart defects can cause
Eisenmenger syndrome, including atrial septal defects [2],
ventricular septal defects, patent ductus arteriosus, and more
complex types of cyanotic heart disease. All these cardio-
vascular alterations can lead to amore or less evident cyanosis
with potential effects favoring the development of chromaffin
cell alterations.
Pheochromocytoma and paraganglioma (P-PGL) are
catecholamine-secreting tumors, which respectively arise
from chromaffin cells of the adrenal medulla and the
sympathetic ganglia. P-PGL are rare tumors representing
about 5% of incidentally discovered adrenal masses [3].
Up to 35-40% of patients have disease-causing germline
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Figure 1: Abdominal CT scan: presence of a big mass in the left
adrenal lodge (6-cmmass).
mutations [4] and the likelihood increases in young pa-
tients.
The coexistence of CHD and P-PGL has already been
reported in previous studies and a causal link between the two
conditions has been postulated [5, 6].
2. Case Presentation
We describe the case of a 23-year-old Caucasian female
affected with congenital tricuspid atresia and intact ventricu-
lar septum. She had a history of palliative surgery since first
days of life but her percutaneous oxygen saturation (SpO2)
level remained around 80% even though a Fontan procedure
was performed at 12 years of age. Persistent desaturation
was related to the presence of venous collaterals between the
Fontan circulation and left atrium.
The patient admitted to Policlinico San Donato (San
Donato Milanese, Italy) for hypertensive crisis, worsening
dyspnea, and hemoptysis. There was no family history of
relevant morbidities. On examination, her height was 175 cm,
weight was 64 kg (BMI 17.7 Kg/m2), blood pressure (BP)
was 160/85mmHg, and SpO2 was 81% (room air). Electro-
cardiogram (ECG) showed sinus tachycardia (heart rate 101
beats/min), first-degree atrioventricular block (PR 220 msec),
and right bundle branch block (QRS 140msec). Chest com-
puted tomography (CT) (Figure 1) incidentally detected a 6-
cm mass in the left adrenal lodge.
The presence of a heterogeneous adrenal lesion, with
hyperintense spots due to hematic content, was confirmed by
abdominal magnetic resonance imaging (MRI) (Figure 2).
Laboratory tests revealed increased levels of noradre-
naline (NA) and its metabolites [plasma NA 5003.7 pg/ml,
n.v. < 480 pg/ml; urinary NA 1059.5𝜇g/24 h, n.v. < 85.5𝜇g/
24 h; urinary metanephrine 489 𝜇g/24 h, n.v. < 320𝜇g/24 h;
plasma adrenaline (A) 100 pg/ml, n.v.20-190 pg/ml; urinary A
15𝜇g/24 h, n.v.1.7-22.4𝜇g/24 h].The patient reported no typi-
cal paroxysmal symptoms of catecholamine excess. Echocar-
diographic evaluation showed slight left atrial and ventricular
enlargement, mild to moderate mitral regurgitation, and
preserved systolic function (ejection fraction 65%).
Figure 2: Abdominal MRI scan: presence of a big heterogeneous
adrenal lesion, with hyperintense spots due to hematic content.
Figure 3: Body 18F-fluorodeoxyglucose positron emission
tomography scan: no significant metabolic activity in the adrenal
mass but intense uptake in supra- and subdiaphragmatic brown
adipose tissue.
The diagnosis of pheochromocytoma was confirmed
by 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy
showing abnormal accumulation of radioactive tracer in
the left adrenal gland. A 18F-fluorodeoxyglucose positron
emission tomography (18F-FDG-PET) performed in order to
exclude any extra-adrenal uptake: no significant metabolic
activity in the adrenal mass but intense uptake in supra- and
subdiaphragmatic brown adipose tissue was detected, likely
due to noradrenergic-stimulated glucose uptake (Figure 3).
The patient underwent open left adrenalectomy after
preconditioning with 𝛼-blockers (doxazosin) and, then, 𝛽-
blockers (bisoprolol). Postoperative course was complicated
by anemia due to hematoma formation in the left hypochon-
drium. Histopathological examination confirmed the diag-
nosis of pheochromocytoma with large hemorrhagic areas
and scarce necrosis. No capsular or lymphovascular invasion
was found. Immunohistochemistry revealed diffuse expres-
sion of chromogranin A, synaptophysin and neuron specific
enolase, and S100 staining in sustentacular cells; Ki-67 was
<5%. The P-PGL susceptibility genes VHL, RET, SDHA,
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SDHAF2, SDHB, SDHC, SDHD, MAX, and TMEM127 were
analyzed for germline mutations and large deletions, via
direct sequencing and multiplex ligation-dependent probe
amplification methods; RET was only analyzed by direct
sequencing. No aberration was found in these genes. Twelve
months after surgery patient’s BP and heart rate were
under control and urinary NA and metanephrine levels
were within the normal range. Plasma NA levels remained
slightly increased (715 pg/ml n.v. 70-480), consistent with the
hemodynamic changes in Fontan circulation [7].
3. Discussion
We present a case of pheochromocytoma in a young patient
affected with congenital tricuspid atresia treated by Fontan
surgery. Several cases of cooccurrence of pheochromocytoma
and CCHD have been described in the literature [5]. It has
been hypothesized that chronic hypoxia plays a fundamental
role in these cases. In the last decades much evidence has
been gathered supporting the role of hypoxia in P-PGL
tumorigenesis. In 1973 Saldana et al. [8] documented a higher
prevalence of carotid body paraganglioma in Peruvian adults
living at high altitude in the Andes compared with those
living at sea level, suggesting a link with chronic hypoxia.
Glomus cells of the carotid body, such as chromaffin cells
of fetal adrenal medulla, are specialized in sensing local
oxygen tension in mammals [9] and can undergo anatomical
changes if exposed to chronic hypoxia [10]. The hypoxia
hypothesis has subsequently been supported since the 2000s
by the discovery of the molecular basis of hereditary P-PGL.
In fact a number of genes implicated in P-PGL syndromes,
including succinate dehydrogenase (SDHx), von Hippel-
Lindau (VHL), and hypoxia induced-factor 2A (HIF2A)
genes, cluster in a common molecular pathway leading to the
abnormal activation and stabilization of hypoxia-inducible
factors (HIFs) in normoxic condition. This dysregulated
accumulation of HIFs induces a number of downstream
genes involved in angiogenesis, tumor growth, apoptosis, and
energy metabolism. These findings have led to the hypoth-
esis that chronic exposure to hypoxia in CCHD patients
may increase the risk of developing P-PGL. In a recent
letter to editor of New England Journal of Medicine Vaidya
and colleagues report the identification of gain-of-function
somatic mutations of EPAS1, which encodes for HIF-2𝛼,
in pheochromocytomas and paragangliomas in four of five
patients who presented with cyanotic congenital heart dis-
ease.The authors concluded that the EPAS1 mutations endow
chromaffin cells exposed to chronic hypoxia amplified the
ability of development of the oncogenic properties of HIF-2𝛼
[11].
Opotowky et al. [12] showed that patients with CCHD
have a greater risk of developing P-PGL [(odds ratio (OR) 6.0]
whereas the OR in those with non-cyanotic CHDdid not dif-
fer from that seen in patients without CHD.The same authors
also pointed out that pheochromocytomas in CCHDpatients
share a number of clinical and biochemical features with
pseudohypoxic PPGL syndromes, such as young age of onset,
multiple tumors, and noradrenergic phenotype, suggesting a
common pathogenetic molecular pathway. Unfortunately, in
this case report, a complete assessment of all currently known
genes involved in P-PGL syndrome has not been performed.
This case displays an exclusive noradrenergic pheno-
type and a young age of onset, suggestive of pseudohy-
poxic pheochromocytoma-paraganglioma syndromes [4].
The patient, although treated immediately after birth, had
sustained prolonged cyanotic episodes in her life. Therefore,
in the light of the above, the cooccurrence of CCHD (as well
as in other numerous case of congenital heart defects that can
cause cyanosis) and P-PGL in this patient could be explained
by exposure to chronic hypoxia. This hypothesis was further
supported by the absence of specific genetic background,
often detectable in P-PGL young patients.
In conclusion, the combination of cyanotic congenital
heart disease with P-PGL is uncommon but clinically rele-
vant. The diagnosis of pheochromocytoma can be difficult
in this clinical setting, as catecholamine excess symptoms
(palpitations, arrhythmias, fatigue, dyspnea, and orthostatic
hypotension) overlap with CCHD complications. Clinicians
should consider P-PGL as a possible and potentially curable
cause of otherwise unexplained clinical deterioration (in this
case a slight hypertensive crisis and worsening dyspnea) in
CCHD patients, even in the absence of typical paroxysmal
symptoms.
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Written informed consent was obtained from the patient for
publication of this case report and any accompanying images.
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